HomeWebinarsTapping the Potential of Gene Editing Technology to Improve Cell-Based Assays for ADME/Tox

Tapping the Potential of Gene Editing Technology to Improve Cell-Based Assays for ADME/Tox


What Does it Cover?

Advances in gene editing technologies have generated a great amount of interest within the scientific community over the past few years. In addition to the ability to make precise double-stranded DNA cuts virtually anywhere in the human genome, new variations of these tools show promise in the ability to activate or repress the expression of individual genes. Besides the obvious interest in clinical applications for these tools, there are practical uses of these tools for modifying and improving in vitro cell-based assays in areas such as preclinical ADME/Tox. This webinar will highlight these recent advances in gene editing technology and provide several examples of how this technology has been applied to ADME/Tox assays, including intestinal, hepatic, and renal proximal tubule cell lines.

What Will You Learn?

  • Review recent advances in gene editing technology to modify the activity of genes of interest
  • Learn about various applications of this technology to the ADME/Tox field
  • Hear specific examples of drug transporter knockout/knockin cell lines

Who Should Attend?

  • Academic researchers
  • Pharma researchers
  • ADME scientists
  • DMPK scientists
  • Toxicology scientists
  • Drug discovery scientists


David C. Thompson

David C. Thompson



Dr. Thompson is Sr. R&D Manager of the In Vitro Safety Systems group for MilliporeSigma in St. Louis, MO. He received his PhD in biochemical toxicology from Johns Hopkins University in Baltimore, MD, followed by post-doctoral work at the Karolinska Institute in Stockholm, Sweden and at the National Institute of Environmental Health Sciences in Research Triangle Park, NC. His research interests primarily focus on the role of bioactivation in toxicology and on the use of in vitro models to explore mechanisms of toxicity. He was a faculty member at Texas A&M University College of Medicine prior to moving to the pharmaceutical industry, where he spent 12 years working in a discovery Drug Safety group as a project team representative and manager of an investigative toxicology laboratory. Dr. Thompson joined Sigma-Aldrich in 2010. His current work focuses on the development of ADME/Tox cell-based bioassays utilizing highly specific genome editing tools such as zinc finger nucleases (ZFNs) and CRISPR.

Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?